40
Participants
Start Date
August 8, 2017
Primary Completion Date
May 25, 2020
Study Completion Date
May 25, 2020
OMO-1
OMO-1 is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase
Mary Crowley Cancer Research, Dallas
University Hospital Antwerp, Edegem
Institut Bergonie, Bordeaux
Hôpital La Timone, Marseille
lnstitut Gustave Roussy, Villejuif
Erasmus MC, Rotterdam
UMCU Universitair Medisch Centrum Utrecht, Utrecht
University College London Hospitals NHS Foundation Trust, London
The Christie NHS Foundation Trust, Manchester
The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne
University of Oxford, Department of Oncology, Oxford
Lead Sponsor
Octimet Oncology N.V.
INDUSTRY